Boston Scientific announced that a recent cyberattack will materially impact its Q3 and full-year 2026 financial results, causing the company to miss previously issued net sales and earnings guidance. This news is a significant negative catalyst for the stock, as it directly impacts near-term financial performance and introduces uncertainty regarding recovery timelines.
Boston Scientific disclosed that a cyberattack in August disrupted global operations, impacting its ability to manufacture, process, and ship orders. This has led the company to anticipate missing its Q3 and full-year 2026 net sales and adjusted EPS guidance, which is a direct negative for investors. While major distribution centers and most manufacturing plants are operational, the full financial fallout and complete system restoration timeline remain unclear. This creates short-term uncertainty and downside risk for BSX shares, as evidenced by the immediate 5.31% drop. However, the company does not foresee long-term material damage, suggesting potential for recovery once operations fully normalize and revised guidance is provided.